{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.67","value":"1407.89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"PK was analyzed only when all patients has completed 12 cycles on treatment or discontinued the study treatment early.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetics Analysis Set (PAS): All patients with at least one evaluable PK blood sample. Of the 32 patients included in the PAS, only 30 had evaluable Ctrough.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8","title":"Pharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients","type":"SECONDARY","unitOfMeasure":"ng/mL"}